Jack Higgins
Technik-/Wissenschafts-/F&E-Leiter bei IMMUNOME, INC.
Vermögen: - $ am 30.04.2024
Profil
Jack Higgins is currently the Chief Scientific Officer at Immunome, Inc. He previously worked as the Chief Development Sciences Officer at Molecular Templates, Inc. from 2010 to 2021 and again from 2019 to 2021.
He also served as the Chief Scientific Officer at MorphImmune, Inc. from 2022 to 2023.
Dr. Higgins obtained his undergraduate degree from Texas A&M University and his graduate and doctorate degrees from The University of Arkansas.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
IMMUNOME, INC.
-.--% | 01.04.2024 | 0 ( -.--% ) | - $ | 30.04.2024 |
Aktive Positionen von Jack Higgins
Unternehmen | Position | Beginn |
---|---|---|
IMMUNOME, INC. | Technik-/Wissenschafts-/F&E-Leiter | 02.10.2023 |
Ehemalige bekannte Positionen von Jack Higgins
Unternehmen | Position | Ende |
---|---|---|
MorphImmune, Inc.
MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | Technik-/Wissenschafts-/F&E-Leiter | 01.10.2023 |
Molecular Templates, Inc. /Old/
Molecular Templates, Inc. /Old/ BiotechnologyHealth Technology Molecular Templates, Inc. operates as a holding company that engages in the discovery and development of immunotoxins for the treatment of cancer and other serious diseases. These are capable of targeting validated therapeutic cell surface receptors but also non-traditional targets that cannot be therapeutically targeted by antibodies or small molecules. Its product pipeline consists of lead candidates for non-Hodgkin's lymphoma, multiple myeloma, and breast cancer. The company was founded by Jean Gariépy and Leigh Revers in 2009 and is headquartered in Georgetown, TX. | Geschäftsführer | 01.06.2019 |
MOLECULAR TEMPLATES, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Jack Higgins
The University of Arkansas | Doctorate Degree |
Texas A&M University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
MOLECULAR TEMPLATES, INC. | Health Technology |
IMMUNOME, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Molecular Templates, Inc. /Old/
Molecular Templates, Inc. /Old/ BiotechnologyHealth Technology Molecular Templates, Inc. operates as a holding company that engages in the discovery and development of immunotoxins for the treatment of cancer and other serious diseases. These are capable of targeting validated therapeutic cell surface receptors but also non-traditional targets that cannot be therapeutically targeted by antibodies or small molecules. Its product pipeline consists of lead candidates for non-Hodgkin's lymphoma, multiple myeloma, and breast cancer. The company was founded by Jean Gariépy and Leigh Revers in 2009 and is headquartered in Georgetown, TX. | Health Technology |
MorphImmune, Inc.
MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | Health Technology |